IDEAYA Biosciences (IDYA) News Today $21.75 +0.02 (+0.09%) Closing price 03:59 PM EasternExtended Trading$21.62 -0.13 (-0.58%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month Low - Here's WhyIDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week Low - Here's WhyFebruary 19 at 2:34 AM | marketbeat.comFY2029 Earnings Forecast for IDYA Issued By WedbushFebruary 18 at 2:39 AM | americanbankingnews.comBrokers Issue Forecasts for IDYA FY2029 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Investment analysts at Wedbush issued their FY2029 EPS estimates for IDEAYA Biosciences in a report issued on Thursday, February 13th. Wedbush analyst R. Driscoll expects that the company will earn $1.20 per share for the year. Wedbush has aFebruary 17, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Issues Earnings ResultsIDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million.February 16, 2025 | marketbeat.comIDEAYA Biosciences' (IDYA) "Overweight" Rating Reiterated at StephensStephens reaffirmed an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday.February 15, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Fiera Capital CorpFiera Capital Corp trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 8.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,184,467 shares of the company's stock after selling 105,35February 14, 2025 | marketbeat.comIdeaya Biosciences price target lowered to $40 from $53 at OppenheimerFebruary 13, 2025 | markets.businessinsider.comIdeaya Biosciences enters additional supply pact with Gilead for IDE397February 13, 2025 | markets.businessinsider.comIDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.8% - Here's What HappenedIDEAYA Biosciences (NASDAQ:IDYA) Shares Down 4.8% - Should You Sell?February 13, 2025 | marketbeat.comIdeaya Biosciences reports Q4 EPS ($1.49), consensus (62c)February 13, 2025 | markets.businessinsider.comIDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 13, 2025 | prnewswire.comIDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLCFebruary 13, 2025 | prnewswire.comIDEAYA Biosciences Appoints Joshua Bleharski, Ph.D. as Chief Financial OfficerSan Francisco, California - February 10, 2025 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has announced the appointment of Joshua Bleharski, Ph.D. as its new Chief Financial OFebruary 13, 2025 | americanbankingnews.comIdeaya Biosciences stock hits 52-week low at $21.02February 12, 2025 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - Should You Sell?IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month Low - Here's What HappenedFebruary 11, 2025 | marketbeat.comIDEAYA Biosciences (IDYA) Projected to Post Earnings on TuesdayIDEAYA Biosciences (NASDAQ:IDYA) will be releasing earnings before the market opens on Tuesday, February 18, Financial Modeling Prep reports.February 11, 2025 | marketbeat.comIDEAYA Biosciences Taps J.P. Morgan Exec for CFOFebruary 10, 2025 | marketwatch.comIDEAYA Biosciences appoints new CFOFebruary 10, 2025 | msn.comIDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial OfficerFebruary 10, 2025 | prnewswire.comWCM Investment Management LLC Takes $6.03 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)WCM Investment Management LLC acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 241,894 shares of the company's stock, valued at approximately $6February 10, 2025 | marketbeat.comQ1 Earnings Estimate for IDYA Issued By Leerink PartnrsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for IDEAYA Biosciences in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will earn ($0.66) perFebruary 10, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by abrdn plcabrdn plc boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 31.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 306,723 shares of the company's stock after purchasing an additional 73,893 shares during the period. abrdn plc owned aboFebruary 9, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have received a consensus rating of "Moderate Buy" from the sixteen research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buFebruary 4, 2025 | marketbeat.comSG Americas Securities LLC Boosts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)SG Americas Securities LLC boosted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 444.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,486 shares of theFebruary 2, 2025 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)January 31, 2025 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations EventsJanuary 27, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (IDYA)January 25, 2025 | ca.finance.yahoo.comCantor Fitzgerald Comments on IDYA FY2025 EarningsIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the coJanuary 22, 2025 | marketbeat.comIDEAYA Biosciences: Promising Pipeline and Strategic Growth Drive Buy RatingJanuary 22, 2025 | markets.businessinsider.comBTIG reiterates Buy on Ideaya stock, cites significant updatesJanuary 21, 2025 | msn.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Lifted by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 17.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 79,780 shares of the company's stock after acquiring an additional 12,029 shares during the period. JJanuary 21, 2025 | marketbeat.comShort Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expands By 10.1%IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,000,000 shares, an increase of 10.1% from the December 15th total of 9,080,000 shares. Approximately 12.9% of the company's stock are sold short. Based on an average trading volume of 889,000 shares, the short-interest ratio is currently 11.2 days.January 19, 2025 | marketbeat.comIdeaya stock touches 52-week low at $22.15 amid market challengesJanuary 17, 2025 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - Here's WhyIDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - Should You Sell?January 17, 2025 | marketbeat.comRBC Capital Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)January 16, 2025 | markets.businessinsider.comIDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday.January 15, 2025 | marketbeat.comIDEAYA Biosciences: Robust Pipeline and Financial Stability Drive Buy RatingJanuary 13, 2025 | markets.businessinsider.comCantor Fitzgerald Reaffirms Overweight Rating for IDEAYA Biosciences (NASDAQ:IDYA)Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday.January 13, 2025 | marketbeat.comIDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate GuidanceJanuary 12, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the sixteen analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, thirteenJanuary 10, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Sees Strong Trading Volume - What's Next?IDEAYA Biosciences (NASDAQ:IDYA) Sees Large Volume Increase - Here's WhyJanuary 3, 2025 | marketbeat.comIdeaya enters license agreement for SHR-4849 with Jiangsu HengruiDecember 30, 2024 | markets.businessinsider.comIDEAYA Biosciences: Strategic Partnership and Promising Clinical Data Support Buy RatingDecember 30, 2024 | markets.businessinsider.comIDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week Low - Here's WhyIDEAYA Biosciences (NASDAQ:IDYA) Sets New 1-Year Low - Should You Sell?December 30, 2024 | marketbeat.comIDEAYA Signs License Agreement For ADC SHR-4849 With Jiangsu Hengrui PharmaDecember 30, 2024 | markets.businessinsider.comIDEAYA Biosciences: Strategic Acquisition and Promising Clinical Data Drive Buy RecommendationDecember 29, 2024 | markets.businessinsider.comIDEAYA Enters License Deal With Hengrui Pharma To Develop SHR-4849 Worldwide Outside Of GreaterChinaDecember 29, 2024 | markets.businessinsider.comIDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid TumorsDecember 29, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)December 27, 2024 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Jane Street Group LLCJane Street Group LLC trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 38.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 79,537 shares of the company's stock after selling 49,476 shares during the perioDecember 23, 2024 | marketbeat.com Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address IDYA Media Mentions By Week IDYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼0.800.60▲Average Medical News Sentiment IDYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼86▲IDYA Articles Average Week Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News Legend Biotech News BridgeBio Pharma News Axsome Therapeutics News Blueprint Medicines News Telix Pharmaceuticals Limited American Depositary Shares News Elanco Animal Health News Lantheus News Nuvalent News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDYA Stock Alerts